Copyright
©The Author(s) 2022.
World J Orthop. Jun 18, 2022; 13(6): 555-563
Published online Jun 18, 2022. doi: 10.5312/wjo.v13.i6.555
Published online Jun 18, 2022. doi: 10.5312/wjo.v13.i6.555
Table 1 Characteristics and outcomes of studies that considered tranexamic acid as a safe drug
Ref. | Tissue | Doses | Time of exposure | Outcome |
Ambra et al[3], 2017 | Animal samples (Yucatan minipigs) | 1, 2, and 4 mg/mL | 1, 3, and 6 h | No effect on cell viability |
Marmotti et al[4], 2016 | Human samples (cartilage and synovial tissues) | 7 mg/mL in both cartilage and synovial tissues | 2 wk for cartilage tissue and 48 h for synovial tissue | No effect on synoviocyte morphology |
Degirmenci et al[1], 2019 | Animal samples (rabbits) | Not mentioned | Not mentioned | Healing rate was improved after TXA administration and no detrimental effects were observed |
Bolam et al[29], 2020 | Human and animal samples | 1, 2, 4, 20, 25, 50, and 100 mg/mL | 10 min, 1 h, 2 h, 4 h, 24 h, and 48 h | No effect on cell viability and morphology when treated at doses lower than 20 mg/mL |
Wang et al[33], 2021 | Human samples (fibroblast cells) | 12, 5, 25, 50, and 100 mg/mL | 10 min, 6 h, 12 h, 24 h, and 48 h | No effect on fibroblast cells in a time- and dose-dependent way |
- Citation: Gkiatas I, Kontokostopoulos AP, Tsirigkakis SE, Kostas-Agnantis I, Gelalis I, Korompilias A, Pakos E. Topical use of tranexamic acid: Are there concerns for cytotoxicity? World J Orthop 2022; 13(6): 555-563
- URL: https://www.wjgnet.com/2218-5836/full/v13/i6/555.htm
- DOI: https://dx.doi.org/10.5312/wjo.v13.i6.555